Diligence memo · auto-generated · as of July 2, 2026
Biodel Inc
Biodel Inc looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Biodel Inc operates in Pharmaceuticals, based in DANBURY.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Biodel Inc has raised $19M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $19M on 2012-06-27.
Most recent recorded round closed around 2012-06-27.
Valuation (modeled)modeled
Provath models Biodel Inc at approximately $629M (range $39M–$2.4B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.85× the median modeled value of Series B Pharmaceuticals companies in 2010–2012 (47 peers) — value vs value, same stage and era. Within the normal band (85% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 14.0 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 65% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 83% of those peers.
Closest niche peers: Celator Pharmaceuticals Inc, Kythera Biopharmaceuticals Inc, Palatin Technologies Inc, Pernix Therapeutics Holdings, Inc., CEBIX Inc.
Peoplefiled
11 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.